Neurology Prior Authorization Automation: Accelerating Patient Access

Klivira delivers comprehensive neurology prior authorization automation, optimizing workflows for high-volume specialty drugs and complex imaging protocols.

Neurology practices and health systems face unique challenges in prior authorization, driven by high-cost specialty drugs, frequent re-authorizations, and stringent documentation requirements. Manual processes lead to delays, denials, and significant administrative burden. Klivira's platform integrates with your EMR to transform this operational bottleneck into an efficient, patient-centered process.

High-Volume Prior Authorization Categories in Neurology

Neurology prior authorization is concentrated in several high-impact areas, demanding meticulous documentation and adherence to payer policies. These include disease-modifying therapies (DMTs) for multiple sclerosis (MS), novel Alzheimer's disease therapeutics, CGRP monoclonal antibodies for migraine prevention, and advanced imaging studies (src: corpus research).

Key PA-Triggering Treatments and Diagnostics

  • MS disease-modifying therapies (e.g., ocrelizumab, natalizumab, oral DMTs)
  • Alzheimer's anti-amyloid antibodies (e.g., lecanemab, donanemab) with biomarker requirements
  • Migraine prevention biologics (CGRP monoclonal antibodies and oral gepants)
  • Spinal muscular atrophy / ALS treatments (e.g., nusinersen, risdiplam, gene therapies)
  • Botox for chronic migraine, spasticity, and dystonia
  • Advanced imaging (e.g., brain MRI, MR angiography, amyloid PET)
  • Neuromodulation devices (e.g., deep brain stimulation, vagus nerve stimulation)

Navigating Complex Documentation and Payer Requirements

Neurology PAs frequently require extensive clinical documentation, often aligned with American Academy of Neurology (AAN) Practice Guidelines (src: aan-guidelines). For instance, MS DMTs demand McDonald criteria diagnosis, EDSS scores, and prior therapy trials. Alzheimer's anti-amyloid antibodies necessitate amyloid confirmation (PET or CSF) and MRI for ARIA screening (src: corpus research). Klivira's platform helps structure and automate the submission of these complex data sets.

Addressing Common Neurology Prior Authorization Denials

Denials in neurology often stem from unmet step therapy requirements for MS DMTs or CGRP migraine prevention, gaps in amyloid biomarker confirmation for AD therapies, or failure to meet chronic migraine criteria for Botox (src: corpus research). Klivira's intelligent workflows pre-empt these issues by guiding staff through required documentation and flagging potential deficiencies before submission.

Klivira's Solution for Neurology Prior Authorization Automation

Klivira's platform is engineered to address the specific workflow constraints of neurology. We automate the collection and submission of data for high-volume specialty drugs, manage periodic re-authorizations for chronic treatments, and integrate with EMRs to pull necessary clinical evidence. Our system incorporates AAN-guideline-aware step-therapy logic and tracks MRI monitoring requirements for specific therapies, streamlining the entire PA lifecycle (src: corpus research).

Frequently asked questions

How does Klivira help with MS DMT prior authorizations?

Klivira automates the collection of critical data points such as McDonald criteria, EDSS scores, relapse history, and prior DMT trials required by payers for MS disease-modifying therapies. Our system incorporates AAN-guideline-aware step-therapy logic to ensure submissions align with payer requirements, reducing denial rates.

Can Klivira manage re-authorizations for chronic neurology treatments?

Yes, Klivira's platform includes robust features for managing periodic re-authorizations common with chronic neurology drugs like MS DMTs and CGRP migraine biologics. The system tracks re-authorization schedules, proactively alerts staff, and automates the re-submission process, ensuring continuous patient access to critical therapies.

How does Klivira support prior authorization for Alzheimer's anti-amyloid therapies?

For Alzheimer's anti-amyloid antibodies, Klivira automates the documentation of essential criteria such as clinical AD diagnosis, amyloid confirmation (PET or CSF), MRI for ARIA screening, and ApoE genotype. This ensures all required evidence is presented accurately, addressing a common reason for denial (src: corpus research).

Does Klivira integrate with our EMR for neurology PA data?

Yes, Klivira offers deep integration capabilities with leading EMR systems. This allows for automated extraction of patient demographics, clinical notes, diagnostic results, and medication histories directly from your EMR, populating prior authorization requests without manual data entry.

How does Klivira address step therapy requirements for CGRP migraine prevention?

Klivira's platform tracks and supports step therapy compliance for CGRP migraine prevention biologics. Our system ensures that documentation of prior oral preventive trial failures and detailed headache diaries are included in the PA submission, aligning with payer protocols and minimizing denials (src: corpus research).

Related coverage

Neurology prior auth workflows

Neurology prior auth coverage by state

Neurology prior authorization by drug

Neurology prior authorization by procedure

Ready to automate prior auth for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo